256 related articles for article (PubMed ID: 24464308)
1. Current state of anticoagulants to treat deep venous thrombosis.
Vo T; Vazquez S; Rondina MT
Curr Cardiol Rep; 2014 Mar; 16(3):463. PubMed ID: 24464308
[TBL] [Abstract][Full Text] [Related]
2. New oral anticoagulants in the management of venous thromboembolism: a major advance?
Sciascia S; Hunt BJ
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):487-8. PubMed ID: 25150440
[No Abstract] [Full Text] [Related]
3. Target-specific oral anticoagulants: practice issues for the clinician.
Plitt A; Giugliano RP
Hosp Pract (1995); 2014 Aug; 42(3):48-61. PubMed ID: 25255406
[TBL] [Abstract][Full Text] [Related]
4. New oral anticoagulants for the treatment of venous thromboembolism.
Agnelli G; Becattini C; Franco L
Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
[TBL] [Abstract][Full Text] [Related]
5. [New approaches in the treatment of deep vein thrombosis].
Nieto Rodríguez JA
Med Clin (Barc); 2012 Oct; 139 Suppl 2():19-23. PubMed ID: 23498068
[TBL] [Abstract][Full Text] [Related]
6. [Introduction].
Valle Bernad R
Rev Clin Esp; 2012 Jan; 212 Suppl 1():1-2. PubMed ID: 23117645
[No Abstract] [Full Text] [Related]
7. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377
[TBL] [Abstract][Full Text] [Related]
8. Re: 'Re. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of VTE: A Systematic Review and Meta-analysis of Phase III Trials'.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):127. PubMed ID: 25882231
[No Abstract] [Full Text] [Related]
9. Re: 'Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
Spanos K; Giannoukas AD
Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):353. PubMed ID: 25556084
[No Abstract] [Full Text] [Related]
10. [New oral anticoagulant agents: the quandary of anticoagulation in the elderly].
Páramo JA
Med Clin (Barc); 2013 Oct; 141(8):346-8. PubMed ID: 23831406
[No Abstract] [Full Text] [Related]
11. Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points for Surgeons.
Hurst KV; Lee R; Milosevic I; Handa A
Eur J Vasc Endovasc Surg; 2015 Jul; 50(1):126-7. PubMed ID: 25933476
[No Abstract] [Full Text] [Related]
12. Response to 'Re: Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
Kakkos SK; Kirkilesis GI; Tsolakis IA
Eur J Vasc Endovasc Surg; 2015 Mar; 49(3):353-4. PubMed ID: 25556083
[No Abstract] [Full Text] [Related]
13. Long-term benefits of preventing venous thromboembolic events.
Cohen AT
Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
[TBL] [Abstract][Full Text] [Related]
14. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
[TBL] [Abstract][Full Text] [Related]
15. Switching between oral anticoagulants.
Strasser KM; Qasem A; Madhusudhana S
Hosp Pract (1995); 2014 Aug; 42(3):68-74. PubMed ID: 25255408
[TBL] [Abstract][Full Text] [Related]
16. Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.
Sattari M; Lowenthal DT
Am J Ther; 2011 Jul; 18(4):332-8. PubMed ID: 20535013
[TBL] [Abstract][Full Text] [Related]
17. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.
Harder S; Graff J
Eur J Clin Pharmacol; 2013 Sep; 69(9):1617-33. PubMed ID: 23619611
[TBL] [Abstract][Full Text] [Related]
18. Disadvantages of VKA and requirements for novel anticoagulants.
Shameem R; Ansell J
Best Pract Res Clin Haematol; 2013 Jun; 26(2):103-14. PubMed ID: 23953899
[TBL] [Abstract][Full Text] [Related]
19. Novel oral anticoagulants: a review of new agents.
Wanat MA
Postgrad Med; 2013 Jul; 125(4):103-14. PubMed ID: 23933899
[TBL] [Abstract][Full Text] [Related]
20. [New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
Oberhofer E
MMW Fortschr Med; 2015 Jan; 157(1):24. PubMed ID: 25743289
[No Abstract] [Full Text] [Related]
[Next] [New Search]
